Mentari adds $200M to migraine mission; Royalty’s latest ATTR-CM dealnews2026-07-22T14:17:01+00:00July 22nd, 2026|Endpoints News|
Gilead and Merck provide HIV data; Dimension Capital announces $800M fundnews2026-07-21T15:30:57+00:00July 21st, 2026|Endpoints News|
Scribe’s $96M IPO; Scholar Rock awaits site classification for apitegromabnews2026-07-20T15:20:34+00:00July 20th, 2026|Endpoints News|
Dimerix buys a kidney injury drug; Arpeggio appears to be winding downnews2026-07-17T14:41:37+00:00July 17th, 2026|Endpoints News|
Dimerix buys a kidney injury drug; Arpeggio appears to be winding downnews2026-07-17T14:41:37+00:00July 17th, 2026|Endpoints News|
Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer’s Hernexeosnews2026-07-16T15:18:38+00:00July 16th, 2026|Endpoints News|
Erasca’s $550M offering; Summit sells an antibioticnews2026-07-14T15:09:41+00:00July 14th, 2026|Endpoints News|
Tris Pharma’s CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialnews2026-07-13T14:30:38+00:00July 13th, 2026|Endpoints News|
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectornews2026-07-10T14:35:48+00:00July 10th, 2026|Endpoints News|
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontnews2026-07-09T14:36:35+00:00July 9th, 2026|Endpoints News|
